

Diabetes and Hypertension Project ECHO* Clinic

*ECHO: Extension of Community Healthcare Outcomes


June 9, 2022

Before we begin:

- Rename your Zoom screen with your name and organization
- Claim CE: text 25395-25389 to 804-625-4041
 - Go to vcuhealth.org/echodmhtn for instructions on creating your account

The Diabetes and Hypertension ECHO is made possible by funding through CDC Cooperative Agreement NU58DP006620-InnoVAte.

Zoom Reminders





- You are all on mute. Please unmute to talk.
- If joining by telephone audio only, press *6 to mute and unmute.
- Use the chat function to speak with our team or ask questions.

ECHO is all teach, all learn



Interactive



Co-management of cases



Peer-to-peer learning



Collaborative problem solving

Helpful Reminders



- Please feel free to eat your lunch or step away briefly if needed
- We are recording and can share sessions upon request
 - Each session's slides are available on www.vcuhealth.org/echodmhtn
- Please do not share any protected health information in your discussion or the chat box
- Project ECHO operates on the "All Teach, All Learn" model
 - Feel free to ask questions in the chat or unmute to ask questions at designated times
 - We're all here to learn from each other and value each person's input and expertise!

VCU Health Diabetes & Hypertension ECHO Clinics



VCU Hu	b Team
Principal Investigator	Dave Dixon, PharmD
Administrative Medical Director ECHO Hub	Vimal Mishra, MD, MMCi
Clinical Experts	Niraj Kothari, MD Trang Le, MD
Project Coordinator/IT Support	Madeleine Wagner

- One-hour ECHO clinics on 2nd Thursdays
- Every ECHO clinic includes a didactic presentation followed by case discussions
- Website: <u>www.vcuhealth.org/echodmhtn</u>
 - Directions for claiming CE can be found here
 - You have up to six days after our session to claim CE by texting **25395-25389** to **804-625-4041**



Disclosures

Trang Le, M.D., has no financial conflicts of interest to disclose.Salvatore Carbone, Ph.D., has no financial conflicts of interest to disclose.There is no commercial or in-kind support for this activity.





Which Diet is Best for my Patient with Diabetes?



Salvatore Carbone, PhD, MS, FHFSA

Assistant Professor Department of Kinesiology & Health Sciences College of Humanities & Science Virginia Commonwealth University Email: scarbone@vcu.edu @totocarbone

Case

- 60 yo Black AA man with history of severe obesity, T2DM, hypertension, obstructive sleep apnea presents to the cardiopharmaconutrition clinic after seen cardiologist and found to have BP 160/91, HR 85 and progressive weight gain (~5-7 kg/year) and heart failure with preserved ejection fraction.
- Body weight 173.4 kg, height 175cm, BMI 56.2 kg/m²
- HbA1c is 7.5%, LDL-c 106 mg/dL, TG 167 mg/dL, creat 0.95, eGFR 98. No allergies, however, not in favor of using <u>daily</u> injectable agents for weight loss as they have been proposed to him before. Currently on fosinopril 10mg, chlorthalidone 25mg BID, VitD and metformin 500mg BID (does not tolerate higher dose) and does not want to take any additional medication at this stage.
- Cardiologist adds for primary prevention: Aspirin 81 mg daily and Rosuvastatin 10 mg daily.



Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report

https://doi.org/10.2337/dci19-0014

Table 1—Goals of nutrition therapy

- To promote and support healthful eating patterns, emphasizing a variety of nutrient-dense foods in appropriate portion sizes, in order to improve overall health and specifically to:

 Improve A1C, blood pressure, and cholesterol levels (goals differ for individuals based on age, duration of diabetes, health history, and other present health conditions. Further recommendations for individualization of goals can be found in the ADA Standards of Medical Care in Diabetes [345])
 - \circ Achieve and maintain body weight goals
 - \circ Delay or prevent complications of diabetes
- To address individual nutrition needs based on personal and cultural preferences, health literacy and numeracy, access to healthful food choices, willingness and ability to make behavioral changes, as well as barriers to change
- To maintain the pleasure of eating by providing positive messages about food choices, while limiting food choices only when indicated by scientific evidence
- To provide the individual with diabetes with practical tools for day-to-day meal planning

Table 2—Academy of Nutrition and Dietetics evidence-based nutrition practice guidelines—recommended structure for the implementation of MNT for adults with diabetes (9)

Initial series of MNT encounters: The RDN should implement three to six MNT encounters during the first 6 months following diagnosis and determine if additional MNT encounters are needed based on an individualized assessment.

MNT follow-up encounters: The RDN should implement a minimum of one annual MNT follow-up encounter.



Consensus recommendations

 Evidence suggests that there is not an ideal percentage of calories from carbohydrate, protein, and fat for all people with or at risk for diabetes; therefore, macronutrient distribution should be based on individualized assessment of current eating patterns, preferences, and metabolic goals.

Type of eating pattern	Description	Potential benefits reported*
USDA Dietary Guidelines For Americans (DGA) (8)	Emphasizes a variety of vegetables from all of the subgroups; fruits, especially whole fruits; grains, at least half of which are whole intact grains; lower- fat dairy; a variety of protein foods; and oils. This eating pattern limits saturated fats and <i>trans</i> fats, added sugars, and sodium.	DGA added to the table for reference; not reviewed as par of this Consensus Report
Mediterranean-style (69,76,85–91)	Emphasizes plant-based food (vegetables, beans, nuts and seeds, fruits, and whole intact grains); fish and other seafood; olive oil as the principal source of dietary fat; dairy products (mainly vogurt and cheese) in low to moderate amounts; typically fewer than 4 eggs/week; red meat in low frequency and amounts; wine in low to moderate amounts; and concentrated sugars or honey rarely.	Reduced risk of diabetes A1C reduction Lowered triglycerides Reduced risk of major cardiovascular events
Vegetarian or vegan (77–80,92–99)	The two most common approaches found in the literature emphasize plant-based vegetarian eating devoid of all flesh foods but including egg (ovo) and/or dairy (lacto) products, or vegan eating devoid of all flesh foods and animal-derived products.	Reduced risk of diabetes A1C reduction Weight loss Lowered LDL-C and non-HDL-
Low-fat (26,45,80,83,100–106)	Emphasizes vegetables, fruits, starches (e.g., breads/ crackers, pasta, whole intact grains, starchy vegetables), lean protein sources (including beans), and low-fat dairy products. In this review, defined as total fat intake $\leq 30\%$ of total calories and saturated fat intake $\leq 10\%$.	Reduced risk of diabetes Weight loss
Very low-fat (107–109)	Emphasizes fiber-rich vegetables, beans, fruits, whole intact grains, nonfat dairy, fish, and egg whites and comprises 70–77% carbohydrate (including 30– 60 g fiber), 10% fat, 13–20% protein.	Weight loss Lowered blood pressure
Low-carbohydrate (110–112)	Emphasizes vegetables low in carbohydrate (such as salad greens, broccoli, cauliflower, cucumber, cabbage, and others); fat from animal foods, oils, butter, and avocado; and protein in the form of meat, poultry, fish, shellfish, eggs, cheese, nuts, and seeds. Some plans include fruit (e.g., berries) and a greater array of nonstarchy vegetables. Avoids starchy and sugary foods such as pasta, rice, potatoes, bread, and sweets. There is no consistent definition of "low" carbohydrate. In this review, a low-carbohydrate eating pattern is defined as reducing carbohydrates to 26–45% of total calories.	A1C reduction Weight loss Lowered blood pressure Increased HDL-C and lowered triglycerides
Very low-carbohydrate (VLC) (110–112)	Similar to low-carbohydrate pattern but further limits carbohydrate-containing foods, and meals typically derive more than half of calories from fat. Often has a goal of 20–50 g of nonfiber carbohydrate per day to induce nutritional ketosis. In this review a VLC eating pattern is defined as reducing carbohydrate to ~26% of total calories.	A1C reduction Weight loss Lowered blood pressure Increased HDL-C and lowered triglycerides
Dietary Approaches to Stop Hypertension (DASH) (81,118,119)	Emphasizes vegetables, fruits, and low-fat dairy products; includes whole intact grains, poultry, fish, and nuts; reduced in saturated fat, red meat, sweets, and sugar-containing beverages. May also be reduced in sodium.	Reduced risk of diabetes Weight loss Lowered blood pressure
Paleo (120–122)	Emphasizes foods theoretically eaten regularly during early human evolution, such as lean meat, fish, shellfish, vegetables, eggs, nuts, and berries. Avoids grains, dairy, salt, refined fats, and sugar.	Mixed results Inconclusive evidence

 Until the evidence surrounding comparative benefits of different eating patterns in specific individuals strengthens, health care providers should focus on the key factors that are common among the patterns:

- Emphasize nonstarchy vegetables.
- Minimize added sugars and refined grains.
- Choose whole foods over highly processed foods to the extent possible.
- Studies using personalized nutrition approaches to examine genetic, metabolomic, and microbiome variations have not yet identified specific factors that consistently improve outcomes in type 1 diabetes, type 2 diabetes, or prediabetes.

How many calories?

Quantity vs Quality...

2 servings per co Serving size	mainer	1	cup (2	255g
		serving	Per c	ontain
Calories	2	20	4	40
		% DV*		% D1
Total Fat	5g	6%	10g	139
Saturated Fat	2g	10%	4g	20%
Trans Fat	5g 2g 0g		0g	
Cholesterol	15mg	5%	30mg	109
Sodium	240mg	10%	480mg	219
Total Carb.	35g	13%	70g	259
Dietary Fiber	6g	21%	12g	439
Total Sugars	7g		14g	
Incl. Added Sugars	4g	8%	8g	169
Protein	6g 7g 4g 9g		18g	
Vitamin D	5mcg	25%	10mcg	50%
Calcium	200mg	15%	400mg	30%
Iron	1mg	6%	2mg	109
Potassium	470mg	10%	940mg	209




How many calories?

Quantity vs **Quality...**

2 servings per cor Serving size	1	cup (2	255g	
	Por	serving		ontain
Calories	2	20	4	40
		% DV*		% D1
Total Fat	5g 2g	6%	10g	139
Saturated Fat	2g	10%	4g	200
Trans Fat	0g		0g	
Cholesterol	15mg	5%	30mg	109
Sodium	240mg	10%	480mg	219
Total Carb.	35g	13%	70g	259
Dietary Fiber	6g	21%	12g	439
Total Sugars	7g		14g	
Incl. Added Sugars	6g 7g 4g	8%	8g	169
Protein	9g		18g	
Vitamin D	5mcg	25%	10mcg	509
Calcium	200mg	15%	400mg	30%
Iron	1mg	6%	2mg	109
Potassium	470mg	10%	940mg	209



In type 2 diabetes, 5% weight loss is recommended to achieve clinical benefit. The goal for optimal outcomes is 10-15% or more when needed and can be feasibly and safely




Look AHEAD Research Group. N Engl J Med 2013;369 (2):145-54

Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial


CU

	Weight-chang	e categories (p	ercentage weig	Jht loss in first y	ear; n=4834
	Gain or stable (<2% loss)	Small loss (≥2-<5%)	Medium loss (≥5-<10%)	Large loss (≥10%)	p value
Primary outcome					
Events per person-years	289/17075	141/7870	154/8570	128/8942	
Crude rate per 100 person-years	1.69	1.79	1.80	1.43	
Unadjusted hazard ratio (95% CI)	1.00	1·07 (0·88–1·31)	1·07 (0·88–1·31)	0·83 (0·67–1·02)	0.21
Adjusted hazard ratio†(95% CI)	1.00	1.08 (0.88–1.33)	1·16 (0·95–1·42)	0·79 (0·64–0·98), p=0·034*	0.17
Secondary outcome					
Events per person-years	422/16699	206/7657	203/8411	186/8792	
Crude rate per 100 person-years	2.53	2.69	2.41	2.12	
Unadjusted hazard ratio (95% CI)	1.00	1·08 (0·91–1·27)	0·96 (0·81–1·13)	0·83 (0·70–0·99), p=0·035*	0.04
Adjusted hazard ratio† (95% CI)	1.00	1.05 (0.88–1.25)	0·97 (0·82–1·16)	0·76 (0·63–0·91), p=0·003*	0.006



Calorie Restriction with or without Time-Restricted Eating in Weight Loss





Liu D et al. N Engl J Med 2022;386(16):1495-1504

Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity The TREAT Randomized Clinical Trial

Total Cohort (iHealth weight	CMT (n = 57 inclu	uded in analysis)		ΔCMT TRE (n = 59 included in analysis)			∆TRE ₽	Difference between	Р	
measurements)	Preintervention	Postintervention	ΔCMT	P value	Preintervention	Postintervention	ΔTRE	value	groups	value
iHealth weight, mean (SD), kg	99.2 (95.1 to 103.3)	98.5 (94.3 to 102.7)	-0.68 (-1.41 to 0.05)	.07	99.2 (95.1 to 103.2)	98.2 (94.1 to 102.4)	-0.94 (-1.68 to -0.20)	.01	-0.26 (-1.30 to 0.78)	.63
Weight change, mean (SD), %	NA	NA	-0.75 (-1.47 to -0.04)	.04	NA	NA	-1.17 (-1.89 to -0.45)	.002	-0.41 (-1.43 to 0.60)	.43

	CMT			ΔCMT	TRE					
In-person cohort	Preintervention (n = 25)	Postintervention (n = 24)	ΔCMT	P value	Preintervention (n = 25)	Postintervention (n = 22)	ΔTRE	∆TRE <i>P</i> value	Difference between groups	P value
Weight, kg ^b	93.0 (87.4 to 98.5)	92.4 (86.9 to 97.9)	-0.57 (-1.40 to 0.26)	.18	92.6 (87.0 to 98.1)	90.9 (85.3 to 96.4)	-1.70 (-2.56 to -0.83)	<.001 ^b	-1.13 (-2.33 to 0.07)	.07
Weight change, %			-0.65 (-1.64 to 0.34)	.19			-1.81 (-2.85 to -0.78)	<.001 ^b	-1.16 (-2.59 to 0.27)	.11
Fat mass, kg ^b	30.7 (27.7 to 33.7)	30.6 (27.6 to 33.6)	-0.03 (-0.66 to 0.60)	.93	30.3 (27.3 to 33.3)	29.8 (26.8 to 32.8)	-0.51 (-1.17 to 0.15)	.13	-0.48 (-1.75 to 0.79)	.3
Fat mass, %	33.0 (30.4 to 35.7)	32.9 (30.3 to 35.6)	-0.07 (-0.55 to 0.42)	.78	32.9 (30.3 to 35.6)	32.8 (30.2 to 35.5)	-0.09 (-0.59 to 0.42)	.74	-0.02 (-0.72 to 0.68)	.96
Visceral fat mass, kg	0.625 (0.529 to 0.721)	0.634 (0.537 to 0.730)	0.0088 (-0.0188 to 0.0364)	.53	0.58 (0.48 to 0.67)	0.576 (0.480 to 0.673)	-0.0026 (-0.0314 to 0.0263)	.86	-0.0114 (-0.0513 to 0.0285)	.58
Subcutaneous fat mass, kg	1.95 (1.74 to 2.17)	1.94 (1.72 to 2.16)	-0.013 (-0.066 to 0.040)	.63	1.87 (1.66 to 2.09)	1.84 (1.62 to 2.06)	-0.038 (-0.093 to 0.017)	.17	-0.025 (-0.101 to 0.051)	.51
Lean mass, kg ^b	59.7 (55.3 to 64.1)	59.3 (55.0 to 63.7)	-0.35 (-0.95 to 0.25)	.25	60.0 (55.6 to 64.4)	58.9 (54.5 to 63.3)	-1.10 (-1.73 to -0.48)	<.001 ^b	-0.75 (-1.96 to 0.45)	.09
Trunk lean mass, kg	30.5 (28.3 to 32.6)	30.3 (28.2 to 32.5)	-0.15 (-0.54 to 0.24)	.45	30.4 (28.3 to 32.6)	30.0 (27.8 to 32.1)	-0.47 (-0.88 to -0.06)	.024°	-0.32 (-0.89 to 0.25)	.27
Appendicular lean mass, kg	25.8 (23.6 to 28.0)	25.6 (23.4 to 27.8)	-0.17 (-0.41 to 0.07)	.16	26.1 (24.0 to 28.3)	25.5 (23.3 to 27.7)	-0.64 (-0.89 to -0.39)	<.001 ^b	-0.47 (-0.82 to -0.12)	.009
Appendicular lean mass index, kg/m ²	8.62 (8.10 to 9.14)	8.56 (8.04 to 9.08)	-0.058 (-0.136 to 0.020)	.14	8.80 (8.28 to 9.32)	8.58 (8.06 to 9.10)	-0.220 (-0.301 to -0.139)	<.001 ^b	-0.162 (-0.274 to -0.050)	.005
Total body water, kg ^c	42.7 (39.6 to 45.8)	42.1 (39.0 to 45.2)	-0.59 (-1.06 to -0.13)	.01	41.9 (38.6 to 45.1)	41.5 (38.3 to 44.7)	-0.36 (-0.85 to 0.13)	.14	0.23 (-0.44 to 0.91)	.5

Lower Physical Activity Level, p=0.033 Greater awake time, p=0.01

Lowe DA et al. JAMA Intern Med 2020;180(11):1491-1499



How many calories?


Quantity vs <u>Quality</u>...

2 servings per co Serving size	1	cup (2	255g	
	En	serving	Por o	ontaine
Calories	2		4	40
		% DV*		% D\
Total Fat	5g	6%	10g	13%
Saturated Fat	5g 2g 0g	10%	4g	20%
Trans Fat	0g		0g	
Cholesterol	15mg	5%	30mg	10%
Sodium	240mg	10%	480mg	219
Total Carb.	35g	13%	70g	25%
Dietary Fiber	6g	21%	12g	43%
Total Sugars	7g		14g	
Incl. Added Sugars	6g 7g 4g 9g	8%	8g	169
Protein	9g		18g	
Vitamin D	5mcg	25%	10mcg	50%
Calcium	200mg	15%	400mg	309
Iron	1mg	6%	2mg	109
Potassium	470mg	10%	940mg	209




Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet


Dietary Intervention Randomized Controlled Trial (DIRECT)



Vertical bars indicate standard errors. To statistically evaluate the changes in weight measurements over time, generalized estimating equations were used, with the low-fat group as the reference group. The explanatory variables were age, sex, time point, and diet group.



Long-Term Effects of Randomization to a Weight Loss Intervention in Older Adults: A Pilot Study



Houston DK et al. J Nutr Gerontol Geriatr 2019;38(1):83-99

How many calories?

Quantity vs <u>Quality</u>...

2 servings per co Serving size	1	cup (2	255g	
	En	serving	Por o	ontaine
Calories	2		4	40
		% DV*		% D\
Total Fat	5g	6%	10g	13%
Saturated Fat	5g 2g 0g	10%	4g	20%
Trans Fat	0g		0g	
Cholesterol	15mg	5%	30mg	10%
Sodium	240mg	10%	480mg	219
Total Carb.	35g	13%	70g	25%
Dietary Fiber	6g	21%	12g	43%
Total Sugars	7g		14g	
Incl. Added Sugars	6g 7g 4g 9g	8%	8g	169
Protein	9g		18g	
Vitamin D	5mcg	25%	10mcg	50%
Calcium	200mg	15%	400mg	309
Iron	1mg	6%	2mg	109
Potassium	470mg	10%	940mg	209




Low-Fat Dietary Pattern and Risk of Cardiovascular Disease


The Women's Health Initiative Randomized Controlled Dietary Modification Trial

- Goal <20% kcal from Fats (and presumed associated <7% from SFA)
- Fruits and vegetables to at least 5 servings/day
- Grains to 6 servings/day
- 18 group sessions for 1st year and then quarterly thereafter


Low-Fat Dietary Pattern and Risk of Treated Diabetes Mellitus in Postmenopausal Women


The Women's Health Initiative Randomized Controlled Dietary Modification Trial





Howard BV et al. *JAMA* 2006;295(6):655-66 Tinker LF et al. *Arch Intern Med* 2008;168(14):1500-11 Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts






	Multivariable-adjusted* Hazard Ratios (95% CI)						
Subgroups	(n, events)	MeDiet + EVOO	MeDiet + Nuts	Control	P for interaction		
Sex							
Men	(3165, 171)	0.73 (0.51-1.04)	0.65 (0.45-0.95)	1 (ref.)			
Women	(4282, 117)	0.64 (0.42-0.98)	0.86 (0.55-1.36)	1 (ref.)	0.37		
Age							
<70 yr	(4776, 133)	0.74 (0.49-1.12)	0.73 (0.48-1.11)	1 (ref.)	0.94		
≥70 yr	(2671, 155)	0.68 (0.47-0.99)	0.74 (0.50-1.11)	1 (ref.)			
Diabetes							
No	(3833, 98)	0.69 (0.43-1.12)	0.66 (0.40-1.07)	1 (ref.)	0.88		
Yes	(3614, 190)	0.69 (0.50-0.97)	0.74 (0.51-1.06)	1 (ref.)			

	MeDiet + Extra-Virgin Olive Oil (n = 2364)		MeDi	MeDiet + Nuts		ol Diet
			(n :	= 2108)	(n = 1941)	
	Baseline	End of trial	Baseline	End of trial	Baseline	End of trial
	Me	an (SD)	Mean (SD)		Mean (SD)	
Energy (kcal)	2,257 ± 550	2,172 ±475	2,276 ± 527	2,229 ±477	2,186 ± 535	1960 ± 497
Total protein (% E)	16.7 ± 2.8	16.2 ±2.4	16.6 ± 2.7	16.4 ±2.5	16.6 ± 2.8	17.1 ± 3.0
Total carbohydrate (% E)	41.7 ± 7.2	40.4 ±5.9	41.4 ± 7.0	39.7 ±6.3	42.2 ± 7.1	43.7 ± 7.0
Fiber (g/d)	25.7 ± 9.1	25.4 ±7.5	25.7 ± 8.6	27.0 ±8.0	24.7 ± 8.4	23.7 ±7.7
Total fat (% E)	39.2 ± 6.9	41.2 ±5.4	39.4 ± 6.5	41.5 ±6.1	39.0 ± 7.0	37.0 ± 7.0
Saturated fatty acids (% E)	10.0 ± 2.2	9.4 ±2	10.0 ± 2.1	9.3 ±2.0	10.0 ± 2.3	9.1 ± 2.1
Monounsaturated fatty acids (% E)	19.6 ± 4.6	22.1 ±3.7	19.6 ± 4.3	20.9 ±4.1	19.3 ± 4.7	18.8 ± 4.6
Polyunsaturated fatty acids (% E)	6.1 ± 2.1	6.1 ±1.4	6.4 ± 2.0	7.7 ±1.8	6.2 ± 2.1	5.5 ± 1.7
Linoleic acid, (g/d)	12.9 ± 6.0	12.2 ±4.6	13.6 ± 6.1	16.0 ±5.5	12.6 ± 6.0	10.0 ± 4.8
α- linolenic acid, (g/d)	1.4 ± 0.7	1.3 ±0.7	1.5 ± 0.7	1.9 ±0.7	1.3±±0.6	1.1 ± 0.5
Marine n-3 fatty acids (g/d)	0.8 ± 0.5	0.9 ±0.5	0.8 ± 0.5	0.8 ±0.5	0.8 ± 0.5	0.7 ± 0.4
Olive oil (% E)	16.3 ±7.1	22.0 ±6.0	15.9 ± 6.7	17.6 ±6.4	15.8 ± 7.4	16.4 ± 6.8
Nuts (% E)	2.5 ±3.4	2.6 ±3.1	3.3 ± 3.7	8.2 ±4.5	2.4 ± 3.2	1.6 ± 2.5
Cholesterol (mg/d)	363 ± 131	339 ±101	367 ± 117	338 ±99	356 ± 122	32 ± 106

OVCU

Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial



Mediterranean Diet (N=502)	Hazard Ratio (95% CI) P-Value for interaction
ants With Primary End-Point	interaction
tal No. Of Participants	
	0.03
67/414	0.68 (0.50-0.94)
20/88	1.27 (0.64-2.49)
	0.127
70/434	0.72 (0.53-0.97)
17/68	0.99 (0.44-2.24)
	0.373
32/246	0.69 (0.43-1.11)
55/256	0.77 (0.55-1.10)


Delgado-Lista J et al. Lancet 2022;399(10338):1876-1885

Table 4—Quick reference conversion of percent calories from carbohydrate shown in grams per day as reported in the research reviewed for this report							
Calories	10%	20%	30%	40%	50%	60%	70%
1,200	30 g	60 g	90 g	120 g	150 g	180 g	210 g
1,500	38 g	75 g	113 g	150 g	188 g	225 g	263 g
2,000	50 g	100 g	150 g	200 g	250 g	300 g	350 g
2,500	63 g	125 g	188 g	250 g	313 g	375 g	438 g

SWEETENERS

Consensus recommendations

- Replace sugar-sweetened beverages (SSBs) with water as often as possible.
- When sugar substitutes are used to reduce overall calorie and carbohydrate intake, people should be counseled to avoid compensating with intake of additional calories from other food sources.





Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report

Consensus recommendations

- In general, <u>replacing saturated fat</u> with unsaturated fats reduces both total cholesterol and LDL-C and also benefits CVD risk.
- In type 2 diabetes, counseling people on eating patterns that replace foods high in carbohydrate with foods lower in carbohydrate and higher in fat may improve glycemia, triglycerides, and HDL-C; emphasizing foods higher in unsaturated fat instead of saturated fat may additionally improve LDL-C.
- People with diabetes and prediabetes are encouraged to consume less than 2,300 mg/day of sodium, the same amount that is recommended for the general population.
- The recommendation for the general public to eat a serving of fish (particularly fatty fish) at least two times per week is also appropriate for people with diabetes.



Diabetes Food Hub	Search recipes	Q	→ Login Menu 🗮
Disque	Corri Salau	Struttp	Herbeu reta Dip
🗿 15 min 📛 7 hr 🛆 6	🗿 20 min 📛 25 min 🛆 6	힌 12 min 💾 8 min 🛆 4	() 15 min () 8



Featured	Featured	Featured Control of the second s	Sponsored Contraction of the second sec
Instant Pot Chicken Curry Salad	Buffalo Chicken Legs with Blue Cheese Salad	Turbot with Watercress and Zucchini	Cod and Grilled Lemon with So Cal Kale & Bean
0 12 min 🛱 23 min 🛆 4	① 10 min □ 20 min △ 4	5 min [™] 20 min 4 Screenshot	0 5 min 🛱 15 min 🛆 2

VCU

https://www.diabetesfoodhub.org/featured-recipes.html

Conclusion

- In patients with T2DM, MNT provided by RDNs plays a central role to improve risk factors as well as long-term clinical outcomes:
 - <u>Weight loss</u> is an effective treatment to improve cardiometabolic risk factors although weight regain is common and likely requires long-term follow-up to be prevented. Also, intermittent fasting is not superior to daily caloric restriction with regards to weight loss and glycemic control.
 - <u>High-(healthy) fat diet</u> (i.e., Mediterranean diet) reduce CVD in primary/secondary prevention independent of changes in body weight in patients with and without T2DM, while low-fat diet appear neutral.
- Dietary interventions in T2DM should be personalized based on cultural and personal preferences.
- Dietary counseling should always include education related to the nutritional management of hypoglycemia in T2DM.
- Treat risk factors, treat risk factors, treat risk factors.



Case

- 60 yo Black AA man with history of severe obesity, T2DM, hypertension, obstructive sleep apnea presents to the cardiopharmaconutrition clinic after seen cardiologist and found to have BP 160/91, HR 85 and progressive weight gain (~5-7 kg/year) and heart failure with preserved ejection fraction.
- Body weight 173.4 kg, height 175cm, BMI 56.2 kg/m²
- HbA1c is 7.5%, LDL-c 106 mg/dL, TG 167 mg/dL, creat 0.95, eGFR 98. No allergies, however, not in favor of using <u>daily</u> injectable agents for weight loss as they have been proposed to him before. Currently on fosinopril 10mg, chlorthalidone 25mg BID, VitD and metformin 500mg BID (does not tolerate higher dose) and does not want to take any additional medication at this stage.
- Cardiologist adds for primary prevention: Aspirin 81 mg daily and Rosuvastatin 10 mg daily.

What are the goals of medical nutrition therapy?

- Weight loss (caloric restriction, ~600 kcal/day (1800-1900 kcal) based on dietary recall to achieve at least 10% of weight loss within 1 year) to improve BP, HbA1c, and quality of life impairments related to HFpEF.
- Improvements in diet quality (lower added sugars, higher unsaturated fatty acids, sodium control)
- Visit with dietitian every 4 weeks for 6 months, and currently every 6-8 weeks
- Increasing physical activity to improve cardiorespiratory fitness level

Results:

- Results at 12 months: 151 kg (-22 kg, 12.7%), BMI 49.3 kg/m², BP 110/70 HR 70, HbA1c 6.9%, LDL 76 mg/dL
- Results at 20 months: 150 kg, BP 118/72 HR 62 (weight gain prevented!!), labs mostly unchanged
- Physical activity: not increased
- What's next?





Which Diet is Best for my Patient with Diabetes?



Salvatore Carbone, PhD, MS, FHFSA

Assistant Professor Department of Kinesiology & Health Sciences College of Humanities & Science Virginia Commonwealth University Email: scarbone@vcu.edu @totocarbone



Questions?



Case Study #2

- Patient is a 62-year-old software engineer, retiring to Thailand with his wife in hopefully late winter of 2022, with type 2 diabetes who presents to follow-up for
 - 1. Type 2 diabetes diagnosed in 2008:
 - Context: Significant aversion to injectable therapy, and confirms this today
 - Severity: Moderate, based on most recent hemoglobin A1c = 9.5% on 03/19/2019, today = 9.7% today
 - Modifying factors: current diabetes regimen is:
 - glipizide (glipiZIDE 10 mg oral tablet)(Rx): 10 mg, PO, twice daily
 - metformin (metFORMIN 1000 mg oral tablet) (Rx): 1,000 mg, PO, twice daily
 - sitagliptin (Januvia 100 mg oral tablet)(Rx): 1 tab, PO, daily
 - previously had adverse reactions to Actos (rash, weight gain, edema)
- Exacerbating factors: Patient reports dietary indiscretions and significantly decreased physical activity due to COVID19 restrictions, although he reports that he is going to be resuming regular physical activity soon with the warmer
- Diet: he has had some success with reducing carbohydrate intake, especially rice, but this has been challenged by recent holiday festivities
- Review of BGs: per recall range 137 348
- Associated signs / symptoms: No polyuria or polydipsia, no hypoglycemia or hypoglycemia symptoms
- Exacerbating factors: Lunar New Year celebrations and related dietary indiscretion.
- Patient expresses a strong preference to avoid any injectable medications, but would be open to considering once weekly GLP-1 receptor agonist if needed in the future
- Diabetes related complications include: + Microalbuminuria, and no neuropathy, no diabetic retinopathy
 - Last Eye Exam: 2 months ago no DR



Case Study #2 cont.

- Current Outpatient Medications:
 - glipiZIDE (Glucotrol) 10 MG tablet, Take 1 tablet by mouth 2 times daily., Disp: , Rfl:
 - hydroCHLOROthiazide (HYDRODiuril) 12.5 MG tablet, Take 1 tablet by mouth daily., Disp: , Rfl:
 - lisinopril (Prinivil, Zestril) 20 MG tablet, Take 1 tablet by mouth daily., Disp: , Rfl:
 - metFORMIN (Glucophage) 1000 MG tablet, Take 1 tablet by mouth 2 times daily., Disp:, Rfl:
 - simvastatin (Zocor) 20 MG tablet, Take 1 tablet by mouth., Disp: , Rfl:
 - SITagliptin (Januvia) 100 MG tablet, See Instructions, TAKE 1 TABLET DAILY, 3 Refills,
- Dispense: 90, tab, Pharmacy EXPRESS SCRIPTS HOME DELIVERY, Disp: , Rfl:
 - ibuprofen 800 MG tablet, Take 1 tablet by mouth 3 times a day as needed., Disp: , Rfl:



Case Study #2 cont.

- Assessment / Plan :
 - 1. Type 2 diabetes, with significant improvement in moderately severe chronic hyperglycemia:
 - no medication changes today per patient preference,
 - Plan to repeat hemoglobin A1c in 3 months, just prior to follow-up virtual visit, he is agreeable to discussing additional medications at that time if no improvement after 3 months of intensive lifestyle modification
 - annual labs overdue, drawn today, see below
 - 2. Hypertension: Condition, uncontrolled, continue HCTZ and increase lisinopril to 40 mg once daily, prescription sent
 - 3. Hyperlipidemia: last LDL at goal, recommended to continue simvastatin 20 mg daily, repeat lipid panel with next lab draw, ordered as below
 - 4. Hypovitaminosis D: Chronic condition, uncertain prognosis, high risk for low vitamin D levels due to very limited time outdoors, repeat today and adjust repletion dose as indicated based on results

Case Studies

- Anyone can submit cases: <u>www.vcuhealth.org/echodmhtn</u>
- Receive feedback from participants and content experts
- Earn **\$150** for submitting and presenting



Provide Feedback

www.vcuhealth.org/echodmhtn

- Feedback
 - Overall feedback related to session content and flow?
 - Ideas for guest speakers?

Send us your feedback

C 🌲 vcuhealth.org/services/telehealth/for-providers/education/diabetes-and-hypertension-project-echo

+

+

+

0

☆

For Providers		
Education		
Diabetes and Hypertension Project ECHO		
Our Team		
Curriculum		
Claiming CE Credit		
Contact Us		
VCU Nursing Home ECHO		
VCU Health Palliative Care ECHO		
Virginia Opioid Addiction ECHO		

Virginia Sickle Cell Disease ECHO

Diabetes and Hypertension Project ECHO

Welcome to the Diabetes and Hypertension Extension for Community Health Outcomes or ECHO, a virtual network of multidisciplinary diabetes and hypertension experts. An ECHO model connects professionals with each other in real-time collaborative virtual sessions on Zoom. Participants present de-identified cases to one another, share resources, connect to each other, and grow in their expertise. This ECHO will address practice level issues and solutions related to managing complex patients with difficult to control diabetes and hypertension. Register now for an ECHO Session!

Network, Participate and Present

- Engage in a collaborative community with your peers.
- Listen, learn and discuss informational and case presentations in real-time.
- Take the opportunity to submit your de-identified case study for feedback from a team of specialists for diabetes and hypertension.
- Provide valuable feedback.
- Claim CE credit by texting in attendance.

Benefits

VCU Diabetes & Hypertension Project ECHO Clinics

2nd Thursdays — 12 p.m. to 1 p.m.

Mark Your Calendars — Upcoming Sessions

Summer Break ECHO to resume August 11

Please register at www.vcuhealth.org/echodmhtn



Thank you for coming!



Text **25395-25389** to **804-625-4041** for CE credit



Reminder: Mute and Unmute to talk Press *6 for phone audio Use chat function for questions